Simcere has been continuously expanding its R&D investments. In 2021, its R&D investment was more than CNY 1.4 billion, accounting for 28.3% of the sales revenue.
With four R&D centers in Shanghai, Nanjing, Beijing and Boston, the company has established a whole-process R&D system integrating drug discovery, pre-clinical development, clinical trials, and drug registration, owns a R&D pipeline project of nearly 60 new drugs, and is conducting 22 clinical studies for registration of 19 potential innovative drugs.